CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (œSurface), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target...
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology has shown investors the ghost of biotech yet to come. Needing shareholder support for its planned merger with Coherus BioSciences, the biotech has warned that outlays triggered by the deal have shrunk its cash runway and will leave Surface needing funding fast if the deal collapses.
Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding...
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical...